Current Report Filing (8-k)
August 14 2020 - 5:23PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 14, 2020
INTERPACE
Biosciences, INC.
(Exact
name of Registrant as specified in its charter)
DELAWARE
|
|
0-24249
|
|
22-2919486
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
Morris
Corporate Center 1, Building C
300
Interpace Parkway,
Parsippany,
NJ 07054
(Address,
including zip code, of Principal Executive Offices)
(855)
776-6419
Registrant’s
telephone number, including area code:
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.01 par value per share
|
|
IDXG
|
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
[ ]
Emerging growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
Interpace
Biosciences, Inc. (the “Company”) expects to file a Notification of Late Filing on Form 12b-25 disclosing that the
Company is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Form 10-Q”)
within the prescribed time period. In July 2020, the Company received letters from several employees, one of whom has left the
Company’s employ, concerning certain employment and billing and compliance matters. In response, the Company informed its
Audit Committee and Regulatory Compliance Committee as well as its independent registered public accounting firm. The Audit Committee
commenced an investigation of these matters with the assistance of independent counsel and an advisor thereto. Currently, the
investigation is still in process and is unable to be completed by the filing deadline for the Form 10-Q.
In addition, the Company expects that when
the Form 10-Q is filed that it will not be in compliance with the Nasdaq Capital Market’s minimum stockholders’ equity
requirements.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Interpace
Biosciences, Inc.
|
|
|
|
|
By:
|
/s/
Jack E. Stover
|
|
Name:
|
Jack
E. Stover
|
|
Title:
|
President
and Chief Executive Officer
|
Date:
August 14, 2020
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024